Nishan Sarna's questions to Biontech SE (BNTX) leadership • Q1 2025
Question
Nishan Sarna, on behalf of Geoff Meacham, asked about the key factors and rationale driving the selection of specific combination therapies, such as ADCs and cell therapies, to be paired with BNT327.
Answer
CEO Ugur Sahin detailed a three-part strategy: 1) combining with other IO pipeline assets like bispecifics, 2) combining with mRNA vaccines to target residual disease, and 3) combining with their ADC portfolio to reduce tumor burden and leverage immunogenic cell death, a concept for which they have preclinical proof of concept.